A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

The future of drug rebates: Are they to be or not to be?

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

Nearly half of all Americans (49 percent) have at least one prescription drug, and 12 percent of the population has five or more, according to 2017 data from the Centers for Drug Control and Prevention (CDC). In 2016, $329 billion was spent on prescription drugs—an increase of nearly 30 percent from 2010.1

With so much money at stake,

Read more

The five Cs of disruption

by Pete Micca, Partner, Deloitte & Touche LLP

What’s shaping the future of health tech investment?


Health care technology investment in 2017 appeared to be all about convergence. In fact, there were no health tech IPOs at all that year.1 The focus seemed to be squarely on expanding industry footprints to gain economies of scale and more control over the continuum of health services.

Read more

Winning the patient-centric race

by Chris Zant, Principal, Deloitte Digital, Deloitte Consulting LLP

Digital technology and the pharma-patient relationship

The evolution of digital technology in health care has been truly breathtaking. Once a few devices and apps in the clinical setting seemed revolutionary. We now see a future with a full-scale digital technology uptake with streamlined reimbursement and back office functions as well as ROI measurement.

Read more

Avoiding a flat line when it comes to risk in health care

by John Condrad, Principal, Deloitte & Touche LLP

A look into the ever-changing technological landscape and risks within the health care industry

Over the past 20 years, hardware (medical devices and wearables) as well as software technologies, have grown exponentially in number and have transformed almost every industry including the health care industry.

These technologies harness smartphones,

Read more

Could changes to funding streams put biomedical innovation at risk?

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

Funding and other support from private organizations and philanthropists has helped keep many medical researchers at the forefront of their fields, which has resulted in some cases in longer life expectancies and a higher quality of life for people affected by certain diseases. To help ensure science funding pipelines continue to be robust—and to help train the next generation of researchers—nonprofit biomedical funding organizations should pay close attention to the changing nature of giving.

Read more

Consumers want connected medical devices, but demand for digital experts could put further strains on the talent pool for medtech

by Pedro Arboleda, Managing Director, Deloitte Monitor

This week, my colleagues and I are attending AdvaMed’s annual MedTech Conference. Participants will hear about the latest innovations, such as new digital products that incorporate the latest advances in wireless technology and increasingly powerful computing capabilities for generating clinical and economic insights. But I worry the industry might overlook another important change that is occurring in parallel—the ability to attract the specific digital talent needed to deliver on the promise of connected medical devices.

Read more